Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38653696 | 0.93 | GPR119 (0.36) | GPR119MAPTTP53ACACBLMNA | |
| SCHEMBL30872359 | 0.85 | MAPT (0.47) | MAPTTP53MEN1USP2HPGD | |
| SCHEMBL30867823 | 0.78 | GPR119 (0.37) | GPR119TP53LMNA | |
| SCHEMBL30911193 | 0.78 | GPR119 (0.37) | GPR119TP53LMNA | |
| SCHEMBL38654250 | 0.78 | MAPT (0.45) | MAPTTP53MEN1USP2HPGD | |
| SCHEMBL38653779 | 0.78 | GPR119 (0.37) | GPR119MAPTTP53ACACBLMNA | |
| SCHEMBL30911221 | 0.77 | GPR119 (0.40) | GPR119MAPTTP53MEN1USP2 | |
| SCHEMBL30911205 | 0.77 | GPR119 (0.40) | GPR119MAPTTP53MEN1USP2 | |
| SCHEMBL30911162 | 0.77 | GPR119 (0.40) | GPR119MAPTTP53MEN1USP2 | |
| SCHEMBL38653873 | 0.75 | GPR119 (0.38) | GPR119MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | GPR119 2581/4885MAPT 4771/4885TP53 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.